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Background
Peanut is one of the most common foods responsible for
food-induced anaphylaxis in adults. Unfortunately, com-
monly used allergen-specific immunotherapy has not been
successful for the treatment of food allergy because of the
high risk of serious side-effects. Therefore, chemically
modified allergen extracts with improved safety character-
istics are being investigated for its potential use in
immunotherapy.
Methods
Peanut extract (PE) from de-fatted peanut powder was
modified by reduction of disulfide bonds and subsequent
alkylation of the free Cys residues resulting in an allergoid
PE (mPE). The potency of PE and mPE to induce PE-spe-
cific IgG was evaluated after i.p. injections in mice. Subse-
quently, mice were sensitized intra-gastrically for PE and
either 1) subcutaneously challenged with different concen-
trations of PE or mPE to assess the safety profile of these
product candidates, or 2) de-sensitized with subcutaneous
injections of either PE or mPE (immunotherapy) for
4-6 weeks, followed by oral and i.p. challenges to assess
the efficacy profile of the preparations. To assess the safety
and efficacy profile of mPE compared to PE, body tem-
perature was measured after challenge as an objective
parameter of an anaphylactic shock response. In addition,
during the course immunotherapy, blood samples were
taken for analysis of antibody responses and mast cell
activation.
Results
PE and mPE were equally potent in inducing PE-specific
IgG antibodies in mice. Mice sensitized for PE experi-
enced severe anaphylactic symptoms upon subcutaneous
challenge with PE. Modified PE did not give rise to such
reactions, even when given up to 100 fold higher
dosages. Immunotherapy with both PE and mPE
resulted in a significant reduction of the anaphylactic
shock response upon systemic challenge. In addition,
both PE and mPE were able to induce strong increases
in the levels of PE-specific IgG1 and IgG2a compared to
non-desensitized mice. Surprisingly, the mucosal mast
cell response after challenge was decreased after immu-
notherapy with PE but not with mPE.
Conclusion
Using in vivo mouse models, we have shown that an aller-
goid preparation of peanut extract has a significantly
improved safety profile compared to its native counterpart
while retaining its immunogenicity and efficacy profile.
Furthermore, this study supports the usefulness of mouse
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